ParkinsonFranceV1, Hal, Corpus, bibRecord, 000093

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Identifieur interne : 000093 ( Hal/Corpus ); précédent : 000092; suivant : 000094

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Auteurs : Annalisa Pinna ; Wai Kin D. Ko ; Giulia Costa ; Elisabetta Tronci ; Camino Fidalgo ; Nicola Simola ; Qin Li ; Mojgan Aghazadeh Tabrizi ; Erwan Bezard ; Manolo Carta ; Micaela Morelli

Source :

Movement Disorders [ 0885-3185 ] ; 2016-02-12.

RBID : Hal:hal-01287719

Abstract

The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior. We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress l-dopa-induced dyskinesia, without impairing l-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. Rotational behavior and abnormal involuntary movements, or disability and l-dopa-induced dyskinesia were evaluated in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, respectively. Moreover, in the rodent striatum, induction of immediate-early gene zif-268, an index of long-term changes, was correlated with dyskinesia. In 6-hydroxydopamine-lesioned rats, combined administration of l-dopa (4 mg/kg) plus eltoprazine (0.6 mg/kg) plus preladenant (0.3 mg/kg) significantly prevented or reduced dyskinetic-like behavior without impairing motor activity. Zif-268 was increased in the striatum of rats treated with l-dopa and l-dopa plus preladenant compared with vehicle. In contrast, rats treated with eltoprazine (with or without preladenant) had lower zif-268 activation after chronic treatment in both the dyskinetic and l-dopa-non-primed groups. Moreover, acute l-dopa plus eltoprazine plus preladenant prevented worsening of motor performance (adjusting step) and sensorimotor integration deficit. Similar results were obtained in MPTP-treated monkeys, where a combination of preladenant with eltoprazine was found to counteract dyskinesia and maintain the full therapeutic effects of a low dose of l-dopa. Our results suggest a promising nondopaminergic pharmacological strategy for the treatment of dyskinesia in PD. © 2016 International Parkinson and Movement Disorder Society.

Url:

https://hal.archives-ouvertes.fr/hal-01287719

DOI: 10.1002/mds.26475

Links to Exploration step

Hal:hal-01287719

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</title>
<author><name sortKey="Pinna, Annalisa" sort="Pinna, Annalisa" uniqKey="Pinna A" first="Annalisa" last="Pinna">Annalisa Pinna</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344278" status="INCOMING">  <orgName>National Research Council of Italy</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-439125" status="INCOMING">  <orgName>Motac Neuroscience, Manchester, United Kingdom. </orgName>
  <desc>    <address>      <country key="GB"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-362249" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-362249" type="direct"><org type="institution" xml:id="struct-362249" status="INCOMING">  <orgName>Motac Neuroscience</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Costa, Giulia" sort="Costa, Giulia" uniqKey="Costa G" first="Giulia" last="Costa">Giulia Costa</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452953" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Neuropsychopharmacology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Tronci, Elisabetta" sort="Tronci, Elisabetta" uniqKey="Tronci E" first="Elisabetta" last="Tronci">Elisabetta Tronci</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452954" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Physiology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Fidalgo, Camino" sort="Fidalgo, Camino" uniqKey="Fidalgo C" first="Camino" last="Fidalgo">Camino Fidalgo</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452954" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Physiology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Simola, Nicola" sort="Simola, Nicola" uniqKey="Simola N" first="Nicola" last="Simola">Nicola Simola</name>
</author>
<author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-439125" status="INCOMING">  <orgName>Motac Neuroscience, Manchester, United Kingdom. </orgName>
  <desc>    <address>      <country key="GB"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-362249" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-362249" type="direct"><org type="institution" xml:id="struct-362249" status="INCOMING">  <orgName>Motac Neuroscience</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Tabrizi, Mojgan Aghazadeh" sort="Tabrizi, Mojgan Aghazadeh" uniqKey="Tabrizi M" first="Mojgan Aghazadeh" last="Tabrizi">Mojgan Aghazadeh Tabrizi</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452955" status="INCOMING">  <orgName>Department of Chemical and Pharmaceutical Sciences</orgName>
  <desc>    <address>      <addrLine> University of Ferrara, Ferrara</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-54905" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-54905" type="direct"><org type="institution" xml:id="struct-54905" status="VALID">  <orgName>University of Ferrara [Ferrara]</orgName>
  <desc>    <address>      <addrLine>Via Savonarola, 9, 44121 Ferrara FE</addrLine>
      <country key="IT"></country>
    </address>
    <ref type="url">http://unife.it/</ref>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID">  <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
  <orgName type="acronym">IMN</orgName>
  <desc>    <address>      <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://imn-bordeaux.org/</ref>
  </desc>
  <listRelation>    <relation active="#struct-259761" type="direct"></relation>
    <relation name="UMR5293" active="#struct-441569" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID">  <orgName>Université de Bordeaux</orgName>
  <orgName type="acronym">UB</orgName>
  <desc>    <address>      <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://www.u-bordeaux.fr/</ref>
  </desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID">  <idno type="IdRef">02636817X</idno>
  <idno type="ISNI">0000000122597504</idno>
  <orgName>Centre National de la Recherche Scientifique</orgName>
  <orgName type="acronym">CNRS</orgName>
  <date type="start">1939-10-19</date>
  <desc>    <address>      <country key="FR"></country>
    </address>
    <ref type="url">http://www.cnrs.fr/</ref>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452954" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Physiology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Morelli, Micaela" sort="Morelli, Micaela" uniqKey="Morelli M" first="Micaela" last="Morelli">Micaela Morelli</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344278" status="INCOMING">  <orgName>National Research Council of Italy</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</hal:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-01287719</idno>
<idno type="halId">hal-01287719</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-01287719</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-01287719</idno>
<idno type="doi">10.1002/mds.26475</idno>
<date when="2016-02-12">2016-02-12</date>
<idno type="wicri:Area/Hal/Corpus">000093</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</title>
<author><name sortKey="Pinna, Annalisa" sort="Pinna, Annalisa" uniqKey="Pinna A" first="Annalisa" last="Pinna">Annalisa Pinna</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344278" status="INCOMING">  <orgName>National Research Council of Italy</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-439125" status="INCOMING">  <orgName>Motac Neuroscience, Manchester, United Kingdom. </orgName>
  <desc>    <address>      <country key="GB"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-362249" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-362249" type="direct"><org type="institution" xml:id="struct-362249" status="INCOMING">  <orgName>Motac Neuroscience</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Costa, Giulia" sort="Costa, Giulia" uniqKey="Costa G" first="Giulia" last="Costa">Giulia Costa</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452953" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Neuropsychopharmacology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Tronci, Elisabetta" sort="Tronci, Elisabetta" uniqKey="Tronci E" first="Elisabetta" last="Tronci">Elisabetta Tronci</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452954" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Physiology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Fidalgo, Camino" sort="Fidalgo, Camino" uniqKey="Fidalgo C" first="Camino" last="Fidalgo">Camino Fidalgo</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452954" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Physiology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Simola, Nicola" sort="Simola, Nicola" uniqKey="Simola N" first="Nicola" last="Simola">Nicola Simola</name>
</author>
<author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-439125" status="INCOMING">  <orgName>Motac Neuroscience, Manchester, United Kingdom. </orgName>
  <desc>    <address>      <country key="GB"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-362249" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-362249" type="direct"><org type="institution" xml:id="struct-362249" status="INCOMING">  <orgName>Motac Neuroscience</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Tabrizi, Mojgan Aghazadeh" sort="Tabrizi, Mojgan Aghazadeh" uniqKey="Tabrizi M" first="Mojgan Aghazadeh" last="Tabrizi">Mojgan Aghazadeh Tabrizi</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452955" status="INCOMING">  <orgName>Department of Chemical and Pharmaceutical Sciences</orgName>
  <desc>    <address>      <addrLine> University of Ferrara, Ferrara</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-54905" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-54905" type="direct"><org type="institution" xml:id="struct-54905" status="VALID">  <orgName>University of Ferrara [Ferrara]</orgName>
  <desc>    <address>      <addrLine>Via Savonarola, 9, 44121 Ferrara FE</addrLine>
      <country key="IT"></country>
    </address>
    <ref type="url">http://unife.it/</ref>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID">  <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
  <orgName type="acronym">IMN</orgName>
  <desc>    <address>      <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://imn-bordeaux.org/</ref>
  </desc>
  <listRelation>    <relation active="#struct-259761" type="direct"></relation>
    <relation name="UMR5293" active="#struct-441569" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID">  <orgName>Université de Bordeaux</orgName>
  <orgName type="acronym">UB</orgName>
  <desc>    <address>      <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://www.u-bordeaux.fr/</ref>
  </desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID">  <idno type="IdRef">02636817X</idno>
  <idno type="ISNI">0000000122597504</idno>
  <orgName>Centre National de la Recherche Scientifique</orgName>
  <orgName type="acronym">CNRS</orgName>
  <date type="start">1939-10-19</date>
  <desc>    <address>      <country key="FR"></country>
    </address>
    <ref type="url">http://www.cnrs.fr/</ref>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Carta, Manolo" sort="Carta, Manolo" uniqKey="Carta M" first="Manolo" last="Carta">Manolo Carta</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-452954" status="INCOMING">  <orgName>Department of Biomedical Sciences, section of Physiology</orgName>
  <desc>    <address>      <addrLine>University of Cagliari, Cagliari</addrLine>
      <country key="IT"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-365814" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-365814" type="direct"><org type="institution" xml:id="struct-365814" status="INCOMING">  <orgName>University of Cagliari</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Morelli, Micaela" sort="Morelli, Micaela" uniqKey="Morelli M" first="Micaela" last="Morelli">Micaela Morelli</name>
<affiliation><hal:affiliation type="institution" xml:id="struct-344278" status="INCOMING">  <orgName>National Research Council of Italy</orgName>
  <desc>    <address>      <country key="FR"></country>
    </address>
  </desc>
</hal:affiliation>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1002/mds.26475</idno>
<series><title level="j">Movement Disorders</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date type="datePub">2016-02-12</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior. We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress l-dopa-induced dyskinesia, without impairing l-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. Rotational behavior and abnormal involuntary movements, or disability and l-dopa-induced dyskinesia were evaluated in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, respectively. Moreover, in the rodent striatum, induction of immediate-early gene zif-268, an index of long-term changes, was correlated with dyskinesia. In 6-hydroxydopamine-lesioned rats, combined administration of l-dopa (4 mg/kg) plus eltoprazine (0.6 mg/kg) plus preladenant (0.3 mg/kg) significantly prevented or reduced dyskinetic-like behavior without impairing motor activity. Zif-268 was increased in the striatum of rats treated with l-dopa and l-dopa plus preladenant compared with vehicle. In contrast, rats treated with eltoprazine (with or without preladenant) had lower zif-268 activation after chronic treatment in both the dyskinetic and l-dopa-non-primed groups. Moreover, acute l-dopa plus eltoprazine plus preladenant prevented worsening of motor performance (adjusting step) and sensorimotor integration deficit. Similar results were obtained in MPTP-treated monkeys, where a combination of preladenant with eltoprazine was found to counteract dyskinesia and maintain the full therapeutic effects of a low dose of l-dopa. Our results suggest a promising nondopaminergic pharmacological strategy for the treatment of dyskinesia in PD. © 2016 International Parkinson and Movement Disorder Society. </div>
</front>
</TEI>
<hal api="V3">          <titleStmt>            <title xml:lang="en">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</title>
            <author role="aut">              <persName>                <forename type="first">Annalisa</forename>
                <surname>Pinna</surname>
              </persName>
              <idno type="halauthorid">1309319</idno>
              <affiliation ref="#struct-344278"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Wai Kin D</forename>
                <surname>Ko</surname>
              </persName>
              <idno type="halauthorid">1307955</idno>
              <affiliation ref="#struct-439125"></affiliation>
              <affiliation ref="#struct-439190"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Giulia</forename>
                <surname>Costa</surname>
              </persName>
              <idno type="halauthorid">1309320</idno>
              <affiliation ref="#struct-452953"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Elisabetta</forename>
                <surname>Tronci</surname>
              </persName>
              <idno type="halauthorid">1059977</idno>
              <affiliation ref="#struct-452954"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Camino</forename>
                <surname>Fidalgo</surname>
              </persName>
              <idno type="halauthorid">1309321</idno>
              <affiliation ref="#struct-452954"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Nicola</forename>
                <surname>Simola</surname>
              </persName>
              <idno type="halauthorid">1232297</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">Qin</forename>
                <surname>Li</surname>
              </persName>
              <idno type="halauthorid">224848</idno>
              <affiliation ref="#struct-439125"></affiliation>
              <affiliation ref="#struct-439190"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Mojgan Aghazadeh</forename>
                <surname>Tabrizi</surname>
              </persName>
              <idno type="halauthorid">1309322</idno>
              <affiliation ref="#struct-452955"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Erwan</forename>
                <surname>Bezard</surname>
              </persName>
              <idno type="halauthorid">537314</idno>
              <affiliation ref="#struct-244085"></affiliation>
              <affiliation ref="#struct-439125"></affiliation>
              <affiliation ref="#struct-439190"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Manolo</forename>
                <surname>Carta</surname>
              </persName>
              <idno type="halauthorid">1190816</idno>
              <affiliation ref="#struct-452954"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">Micaela</forename>
                <surname>Morelli</surname>
              </persName>
              <idno type="halauthorid">1309323</idno>
              <affiliation ref="#struct-344278"></affiliation>
              <affiliation ref="#struct-452953"></affiliation>
            </author>
            <editor role="depositor">              <persName>                <forename>Chantal</forename>
                <surname>GUERIN</surname>
              </persName>
              <email type="md5">eb4bde61f74652335183b0bd05630b2c</email>
              <email type="domain">u-bordeaux.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>            <edition n="v1" type="current">              <date type="whenSubmitted">2016-03-14 10:22:18</date>
              <date type="whenModified">2016-03-15 01:00:23</date>
              <date type="whenReleased">2016-03-14 10:22:18</date>
              <date type="whenProduced">2016-02-12</date>
            </edition>
            <respStmt>              <resp>contributor</resp>
              <name key="321070">                <persName>                  <forename>Chantal</forename>
                  <surname>GUERIN</surname>
                </persName>
                <email type="md5">eb4bde61f74652335183b0bd05630b2c</email>
                <email type="domain">u-bordeaux.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>            <distributor>CCSD</distributor>
            <idno type="halId">hal-01287719</idno>
            <idno type="halUri">https://hal.archives-ouvertes.fr/hal-01287719</idno>
            <idno type="halBibtex">pinna:hal-01287719</idno>
            <idno type="halRefHtml">Movement Disorders, Wiley, 2016, <10.1002/mds.26475></idno>
            <idno type="halRef">Movement Disorders, Wiley, 2016, <10.1002/mds.26475></idno>
          </publicationStmt>
          <seriesStmt>            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
          </seriesStmt>
          <notesStmt>            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>            <biblStruct>              <analytic>                <title xml:lang="en">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.</title>
                <author role="aut">                  <persName>                    <forename type="first">Annalisa</forename>
                    <surname>Pinna</surname>
                  </persName>
                  <idno type="halauthorid">1309319</idno>
                  <affiliation ref="#struct-344278"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Wai Kin D</forename>
                    <surname>Ko</surname>
                  </persName>
                  <idno type="halauthorid">1307955</idno>
                  <affiliation ref="#struct-439125"></affiliation>
                  <affiliation ref="#struct-439190"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Giulia</forename>
                    <surname>Costa</surname>
                  </persName>
                  <idno type="halauthorid">1309320</idno>
                  <affiliation ref="#struct-452953"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Elisabetta</forename>
                    <surname>Tronci</surname>
                  </persName>
                  <idno type="halauthorid">1059977</idno>
                  <affiliation ref="#struct-452954"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Camino</forename>
                    <surname>Fidalgo</surname>
                  </persName>
                  <idno type="halauthorid">1309321</idno>
                  <affiliation ref="#struct-452954"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Nicola</forename>
                    <surname>Simola</surname>
                  </persName>
                  <idno type="halauthorid">1232297</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Qin</forename>
                    <surname>Li</surname>
                  </persName>
                  <idno type="halauthorid">224848</idno>
                  <affiliation ref="#struct-439125"></affiliation>
                  <affiliation ref="#struct-439190"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Mojgan Aghazadeh</forename>
                    <surname>Tabrizi</surname>
                  </persName>
                  <idno type="halauthorid">1309322</idno>
                  <affiliation ref="#struct-452955"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Erwan</forename>
                    <surname>Bezard</surname>
                  </persName>
                  <idno type="halauthorid">537314</idno>
                  <affiliation ref="#struct-244085"></affiliation>
                  <affiliation ref="#struct-439125"></affiliation>
                  <affiliation ref="#struct-439190"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Manolo</forename>
                    <surname>Carta</surname>
                  </persName>
                  <idno type="halauthorid">1190816</idno>
                  <affiliation ref="#struct-452954"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Micaela</forename>
                    <surname>Morelli</surname>
                  </persName>
                  <idno type="halauthorid">1309323</idno>
                  <affiliation ref="#struct-344278"></affiliation>
                  <affiliation ref="#struct-452953"></affiliation>
                </author>
              </analytic>
              <monogr>                <idno type="halJournalId" status="VALID">17211</idno>
                <idno type="issn">0885-3185</idno>
                <idno type="eissn">1531-8257</idno>
                <title level="j">Movement Disorders</title>
                <imprint>                  <publisher>Wiley</publisher>
                  <date type="datePub">2016-02-12</date>
                </imprint>
              </monogr>
              <idno type="pubmed">26871939</idno>
              <idno type="doi">10.1002/mds.26475</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>            <langUsage>              <language ident="en">English</language>
            </langUsage>
            <textClass>              <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior. We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress l-dopa-induced dyskinesia, without impairing l-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. Rotational behavior and abnormal involuntary movements, or disability and l-dopa-induced dyskinesia were evaluated in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, respectively. Moreover, in the rodent striatum, induction of immediate-early gene zif-268, an index of long-term changes, was correlated with dyskinesia. In 6-hydroxydopamine-lesioned rats, combined administration of l-dopa (4 mg/kg) plus eltoprazine (0.6 mg/kg) plus preladenant (0.3 mg/kg) significantly prevented or reduced dyskinetic-like behavior without impairing motor activity. Zif-268 was increased in the striatum of rats treated with l-dopa and l-dopa plus preladenant compared with vehicle. In contrast, rats treated with eltoprazine (with or without preladenant) had lower zif-268 activation after chronic treatment in both the dyskinetic and l-dopa-non-primed groups. Moreover, acute l-dopa plus eltoprazine plus preladenant prevented worsening of motor performance (adjusting step) and sensorimotor integration deficit. Similar results were obtained in MPTP-treated monkeys, where a combination of preladenant with eltoprazine was found to counteract dyskinesia and maintain the full therapeutic effects of a low dose of l-dopa. Our results suggest a promising nondopaminergic pharmacological strategy for the treatment of dyskinesia in PD. © 2016 International Parkinson and Movement Disorder Society. </abstract>
          </profileDesc>
        </hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000093 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Hal/Corpus/biblio.hfd -nk 000093 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Hal
   |étape=   Corpus
   |type=    RBID
   |clé=     Hal:hal-01287719
   |texte=   Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri